INDIANAPOLIS, May 20, 2014 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the establishment of a strategic alliance with Pathology, Inc. in Torrance, Calif., that designates the company as a Roche Molecular Center of Excellence (MCOE) for the next five years.

Established in 2002, Roche's MCOE program is designed to create an alliance network that enables non-competing regional laboratories across the U.S. to collaborate and capitalize on scientific knowledge in molecular testing and, in turn, help accelerate the advancement of new test methods and technology.

"Roche is very pleased to welcome Pathology, Inc. into the Molecular Center of Excellence alliance," said Whitney Green, senior vice president, molecular diagnostics at Roche Diagnostics Corporation. "We value their expertise in women's health and look forward to working together in implementing molecular technologies in the advancement of personalized medicine."

Pathology, Inc. is one of 35 labs in the U.S. that have received this recognition and joined in this strategic partnership with Roche. "This relationship with Roche will help keep Pathology, Inc. on the leading edge of women's health services and will help ensure that we are supporting physicians and their patients with the most advanced molecular technologies," said Vicki DiFrancesco, president and CEO at Pathology, Inc. "It will also integrally support our mission to help doctors personalize patient care."

As a nationally recognized Roche MCOE, the Pathology, Inc. molecular diagnostics laboratory will offer physicians and patients some of the latest and most advanced molecular technologies, such as Roche's cobas HPV Test, a screening test approved by the FDA for use in helping clinicians assess patients'risk of cervical cancer based on the presence of clinically relevant high-risk HPV DNA.

About Pathology, Inc. Pathology, Inc. is the country's premier full-service independent Women's Health laboratory, providing expertise in reproductive FDA donor testing as well as anatomic, molecular and digital pathology services. Its integrated diagnostic services help doctors personalize patient care to optimally treat disease and maintain health and wellness. The company is committed to providing only the highest level of testing quality and service and working with physicians to provide unique solutions to their most challenging needs.

About Roche Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.

In 2013 the Roche Group employed over 85,000 people worldwide, invested 8.7 billion Swiss francs in R&D and posted sales of 46.8 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit http://www.roche.com or http://www.usdiagnostics.roche.com.

COBAS is a trademark of Roche. All trademarks mentioned in this release are protected by law.

For further information, please contact:

See the article here:

Roche Diagnostics recognizes Pathology, Inc as Roche Molecular Center of Excellence